The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Existing Drugs
Akynzeo (Netupitant-Palonosetron FDC)
Aloxi (Palonosetron)
Emend (Aprepitant)
Kytril Generic (Granisetron)
Zofran Generic (Ondansetron)
Pipeline Drugs
SUSTOL (Granisetron Injection extended release)
Rolapitant
Segment by Application
Serotonin Receptor Antagonists
NK1 Receptor Antagonists
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Merck & Co., Inc.
GlaxoSmithKline plc
Tesaro, Inc.
Helsinn Group
F. Hoffmann-La Roche Ltd.
Heron Therapeutics, Inc.
Dr. Reddy's Laboratories Ltd.
Acacia Pharma
Sun Pharmaceutical Industry Ltd.
Otsuka Holdings Co., Ltd.
